Barriers to Cervical Cancer Screening among transgender men / Barreiras ao exame do Câncer do Colo do Útero entre homens transgêneros
DOI:
https://doi.org/10.34119/bjhrv5n3-293Keywords:
Cervical Cancer, HPV, Pap test, transmasculine, health behavior.Abstract
Purpose: to evaluate the barriers to cervical cancer screening among transgender men, and also to understand their experiences and preferences for cervical cancer screening. Methods: 19-item online survey structured based on the Health Belief Model, a conceptual formulation for understanding why individuals do or do not engage in health-related actions. It consists of the following dimensions: perceived susceptibility, perceived severity, perceived benefits, perceived barriers and general health motivation. Familiarity with cervical cancer, with Human Papillomavirus (HPV) and with Pap Test, being up-to-date on Pap Tests and preference for HPV self-sampling were additionally assessed. Results: 27 transgender men aged 18-51 years completed the survey. Most of them have a formal job, income up to 1 minimum wage per month, and are health-insured. The majority is single, heterossexual, and completed high school. Despite the fact that most are familiar with HPV and cervical cancer and are aware of the importance of regular Pap Tests, less than 20% are up-to-date. The barriers to cervical cancer screening may be related to discrimination, fear of invasive procedures and also the gaps in preventive health care associated with Covid-19. Only 25.9% of participants preferred HPV self-sampling over provider-collected Pap Test screening. Conclusion: most participants were not up-to-date on Pap Test screening, and refer unpleasant experiences in the past, discrimination and fear of invasive procedures. Healthcare professionals should be aware of the needs of this specific population, in order to provide better care and to affirm the gender identity.
References
Coleman E, et al. Standards of Care For The Health Of Transsexual, Transgender and Gender-Nonconforming People. World Professional Association for Transgender Health. 2012. Version 7.
Goodman M, et al. Size and Distribution of Transgender and Gender Nonconforming Populations: A Narrative Review. Endocrinol Metab Clin N Am. 2019;48:303-321.
Rocon PC, et al. Dificuldades vividas por pessoas trans no acesso ao Sistema Único de Saúde. Ciência & Saúde Coletiva. 2016;21(8):2517-2525.
Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). Estimativa 2020 - Incidência do Câncer no Brasil. Ministério da Saúde. 2020.
Ferlay J, et al. Global Cancer Observatory: Cancer Today. 2020. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed 14 Jun 2021.
Burd EM. Human Papillomavirus and Cervical Cancer. Clin. Microbiol. Rev. 2003;16(1):1-17.
Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). Diretrizes Brasileiras Para Rastreamento do Câncer do Colo do Útero. Ministério da Saúde. 2016.
Peitzmeier SM, et al. Pap Test Use Is Lower Among Female-to-Male Patients Than Non-Transgender Women. Am J Prev Med. 2014;47(6):808-812.
Bethlehem J. Selection bias in web surveys. International Statistical Review. 2010;78(2):161-188.
Janz NK, Becker MH. The Health Belief Model: A Decade Later. Health Education Quarterly. 1984;11(1):1-47.
Ben-Natan M, Adir O. Screening for cervical cancer among Israeli lesbian women. International Nursing Review. 2009;56:433-441.
Seay J, et al. Understanding Transgender Men


